newsfilter
← Latest News
GlobeNewswire·

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

PCVX
  • Vaxcyte, Inc. (NASDAQ: PCVX) has commenced an underwritten public offering of $500,000,000 in common stock & pre-funded warrants.
  • The offering includes a 30-day option for underwriters to purchase up to an additional $75,000,000 of shares.
  • BofA Securities, Jefferies, Leerink Partners, Evercore ISI & Guggenheim Securities are acting as joint book-running managers.
  • The offering is subject to market conditions with no assurance regarding completion, size, or terms.
  • A shelf registration statement filed with the SEC on May 24, 2024, was automatically effective upon filing.
  • Vaxcyte is developing VAX-31 (31-valent PCV) in Phase 3 adult & Phase 2 infant trials to prevent invasive pneumococcal disease.
  • Vaxcyte is also developing VAX-24 (24-valent PCV), VAX-XL (earlier-stage), VAX-A1 (Group A Strep), & VAX-GI (Shigella).
  • The company utilizes its XpressCF® cell-free protein synthesis platform to accelerate vaccine development.